End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
20.1 CNY | -5.55% |
|
-9.09% | -32.62% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.62% | 1.23B | - | ||
+20.60% | 43.29B | B- | ||
+27.64% | 22.38B | B+ | ||
+19.96% | 15.51B | - | ||
+19.14% | 14.52B | B+ | ||
+55.11% | 12.93B | B | ||
-0.05% | 6.79B | - | - | |
-11.39% | 6.56B | B+ | ||
+17.73% | 5.87B | B+ | ||
-8.87% | 5.73B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300723 Stock
- Ratings ApicHope Pharmaceutical Co., Ltd